Literature DB >> 12115360

Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group.

Andrea Ferrari1, Michela Casanova, Gianni Bisogno, Adrian Mattke, Cristina Meazza, Lorenza Gandola, Guido Sotti, Giovanni Cecchetto, Dieter Harms, Eva Koscielniak, Jorn Treuner, Modesto Carli.   

Abstract

BACKGROUND: Clear cell sarcoma (CCS) of tendons and aponeuroses is extremely rare in childhood and little information is available on its clinical management. Originally believed to be a type of melanoma of soft tissue origin, CCS is now considered a distinct clinicopathologic entity that behaves like a high-grade soft tissue sarcoma. We report on a series of 28 pediatric patients treated from 1980 to 2000 by the Soft Tissue Sarcoma Italian Cooperative Group and the German Cooperative Group.
METHODS: Patients were treated with a multimodality therapeutic approach. Surgical resection was complete in 17 patients (mutilating in 3), radiotherapy was administered to 8 patients, and 20 patients received chemotherapy.
RESULTS: After a median follow-up of 102 months (range, 19-238 months), the 5-year and event-free survival rates were 66.4% and 63.3%, respectively. Seventeen patients were alive in first remission, two were alive in second remission, and nine had died of disease. The response to chemotherapy in the 7 evaluable patients included one partial remission, one minor response, and five no responses. Radiotherapy contributed to achieving local control in four of six Intergroup Rhabdomyosarcoma Study (IRS) Group II patients. Statistically significant differences in outcome were evident according to IRS group, tumor size, and site.
CONCLUSIONS: Our study confirms the aggressive behavior of CCS. Complete surgical resection represents the mainstay of treatment, and even the only treatment for patients with small tumors. Radiotherapy may control microscopic residual disease after surgery. Chemotherapy is ineffective and the prognosis is unfavorable for patients with unresectable and large tumors. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12115360     DOI: 10.1002/cncr.10597

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Clear cell sarcoma-A review.

Authors:  Rami Mossad Ibrahim; Signe Steenstrup Jensen; Jacob Juel
Journal:  J Orthop       Date:  2018-09-06

2.  Chemotherapy in clear cell sarcoma.

Authors:  Robin L Jones; Anastasia Constantinidou; Khin Thway; Sue Ashley; Michelle Scurr; Omar Al-Muderis; Cyril Fisher; Cristina R Antonescu; David R D'Adamo; Mary Louise Keohan; Robert G Maki; Ian R Judson
Journal:  Med Oncol       Date:  2011-09       Impact factor: 3.064

3.  Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases.

Authors:  Michiaki Karita; Hiroyuki Tsuchiya; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hideji Nishida
Journal:  Int J Clin Oncol       Date:  2011-11-01       Impact factor: 3.402

4.  A Case of Clear Cell Sarcoma Occurring on the Abdomen.

Authors:  Suck Joon Jung; Na Reu Seung; Eun Ju Park; Chul Woo Kim; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2008-03-31       Impact factor: 1.444

5.  Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Authors:  Karl-Ludwig Schaefer; Kristin Brachwitz; Yvonne Braun; Raihanatou Diallo; Daniel H Wai; Susanne Zahn; Dominik T Schneider; Cornelius Kuhnen; Arabel Vollmann; Gero Brockhoff; Helmut E Gabbert; Christopher Poremba
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

6.  EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice.

Authors:  Kazunari Yamada; Takatoshi Ohno; Hitomi Aoki; Katsunori Semi; Akira Watanabe; Hiroshi Moritake; Shunichi Shiozawa; Takahiro Kunisada; Yukiko Kobayashi; Junya Toguchida; Katsuji Shimizu; Akira Hara; Yasuhiro Yamada
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 7.  Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts.

Authors:  Af Mavrogenis; G Bianchi; Na Stavropoulos; Pj Papagelopoulos; P Ruggieri
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

8.  Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines.

Authors:  Marimu Sakumoto; Rieko Oyama; Mami Takahashi; Yoko Takai; Fusako Kito; Kumiko Shiozawa; Zhiwei Qiao; Makoto Endo; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-12-01       Impact factor: 2.416

9.  Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases.

Authors:  O Hocar; A Le Cesne; S Berissi; P Terrier; S Bonvalot; D Vanel; A Auperin; C Le Pechoux; B Bui; J M Coindre; C Robert
Journal:  Dermatol Res Pract       Date:  2012-05-30

10.  Sequential dose-dense Doxorubicin and Ifosfamide in advanced soft-tissue sarcoma patients in an out-patient-basis schedule.

Authors:  G F G Almeida; G Castro; I M L Snitcovsky; S A Siqueira; E H Akaishi; O P Camargo; C R G C M Oliveira; M H H Federico
Journal:  Sarcoma       Date:  2011-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.